Transcription beyond annotated gene boundaries expands the diversity of the cancer transcriptome with overexpressed oncogenes and RNA chimeras.

HOXA9 is a transcriptional maintenance factor for anti-apoptotic genes that accelerate MYC-driven leukemia.

In contrast with earlier conclusions, negative selection has a major role in cancer evolution.

Definition of leukemia gene expression mechanisms reveals general principles of cancer gene control and offers a pharmacologic strategy for its therapeutic reprogramming.

Libraries of patient-derived tumor organoids are a reliable and scalable model system that can help identify and optimize targeted therapies in a pre-clinical setting.

A functional ovarian-specific PAX8-centric regulon is susceptible to FDA-approved HDAC inhibitors, providing the rationale to target human cancers driven by lineage-survival oncogenes with epigenetic therapeutics perturbing the enhancer topology.

ELYS, a multifunctional protein with critical roles in the cell cycle, is essential for the vigorous proliferation and survival of difficult-to-treat cancers carrying mutations in the KRAS oncogene, making it a compelling target for novel drug treatments.

The transcription factor STAT5 mediates the increased breast cancer risk associated with a late age pregnancy, but intermittent anti-STAT5 treatment can lower this risk and thus prevent breast cancer.